Omeros Corporation
Clinical trials sponsored by Omeros Corporation, explained in plain language.
-
Kidney disease drug trial halted midway
Disease control TerminatedThis study tested a drug called OMS721 in 360 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal was to see if the drug could lower protein levels in urine, a sign of kidney damage. The trial was stopped early, so results are limited.
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 17, 2026 11:31 UTC
-
Experimental drug tested for rare blood disorder
Disease control TerminatedThis study tested a drug called OMS721 (narsoplimab) in adults and teenagers with a rare blood disease called atypical hemolytic uremic syndrome (aHUS). The goal was to see if the drug could improve platelet counts and was safe. The study was stopped early and included only 6 par…
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Experimental drug targets protein leak in kidney patients
Disease control TerminatedThis study tested a drug called OMS721 (narsoplimab) in 31 people with four types of kidney disease: IgA nephropathy, lupus nephritis, membranous nephropathy, and C3 glomerulopathy. The main goal was to see if the drug is safe and if it reduces protein in the urine, a sign of kid…
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 11, 2026 20:49 UTC